Company Description

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.

It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.

It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.

FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

FibroBiologics, Inc.

Country	United States
Founded	2021
IPO Date	Jan 31, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	Peter O'Heeron

Contact Details

Address: 455 E. Medical Center Blvd, Suite 300 Houston, Texas 77598 United States
Phone	281-671-5152
Website	fibrobiologics.com

Stock Details

Ticker Symbol	FBLG
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$30.00
CIK Code	0001958777
Employer ID	86-3329066
SIC Code	2834

Key Executives

Name	Position
Peter O'Heeron	Founder, Chairman and Chief Executive Officer
Mark C. Andersen C.F.A., CPA, M.B.A.	Chief Financial Officer
Dr. Hamid Khoja Ph.D.	Chief Scientific Officer
Ruben A. Garcia	General Counsel

Latest SEC Filings

Date	Type	Title
Jun 27, 2024	PRE 14A	Other preliminary proxy statements
Jun 27, 2024	8-K	Current Report
Jun 26, 2024	424B4	Prospectus
Jun 25, 2024	EFFECT	Notice of Effectiveness
Jun 18, 2024	S-1	General form for registration of securities under the Securities Act of 1933
Jun 10, 2024	DRS	[Cover] Draft Registration Statement
Jun 6, 2024	RW	Filing
Jun 4, 2024	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
May 15, 2024	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
May 15, 2024	S-8	Securities to be offered to employees in employee benefit plans

View All SEC Filings